Klinik für Urologie, Charité - Universitätsmedizin Berlin.
With the introduction of targeted drug therapies, a paradigm shift for the treatment of metastatic renal cell carcinoma has taken place. New compounds like sunitinib, sorafenib, bevacizumab and temsirolimus have become established as new therapeutic standards to replace the use of cytokines as standard therapy. Recently, these substances have been complemented by everolimus and pazopanib. An interdisciplinary consensus conference was held to discuss which criteria to consider when using these drugs (treatment sequence) and what questions remain unanswered based on the current study situation (open questions). Results from the 2009 conference provided the basis for the 2010 meeting. The results of the 2010 conference are presented as short theses.
Article in German.
Written by:
Miller K, Bergmann L, Gschwend J, Keilholz U. Are you the author?
Reference: Aktuelle Urol. 2011 Jul;42(4):242-6.
PubMed Abstract
PMID: 21720974
UroToday.com Renal Cancer Section
